JANVIT LTD

Company number 03879642 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

JANVIT LTD – Industry Context Analysis

1. Industry Classification

JANVIT LTD operates within SIC Code 46460 (Wholesale of pharmaceutical goods) with a secondary classification of 46900 (Non-specialised wholesale trade). This places the company in the UK pharmaceutical wholesale and distribution sector – a market estimated at approximately £18-20 billion annually, characterised by high regulatory barriers, stringent MHRA compliance requirements, and significant consolidation among major players.

The pharmaceutical wholesale industry in the UK is dominated by a small number of large-scale operators – notably Alliance Healthcare (part of Walgreens Boots Alliance), AAH Pharmaceuticals (part of Phoenix Group), and Movianto UK – which collectively control the majority of market volume through vertically integrated supply chains serving NHS trusts, community pharmacies, and dispensing practices. Smaller wholesalers typically occupy niche positions as short-line distributors, parallel importers, or specialist cold-chain logistics providers.

Key sector characteristics include: - Low margins: Typical gross margins of 2-5% on pharmaceutical distribution, driven by NHS drug tariff pricing and Category M concessions - High working capital requirements: Substantial debtor books due to extended NHS payment terms and manufacturer rebates - Regulatory overhead: GDP (Good Distribution Practice) compliance, FMD (Falsified Medicines Directive) verification, and MHRA licensing obligations - Scale advantages: Larger operators benefit from purchasing leverage, automated warehousing, and distribution network density

2. Relative Performance

JANVIT LTD's financial trajectory reveals a company in long-term secular decline, with performance metrics falling well below industry norms across multiple dimensions:

Metric JANVIT LTD (2024) Typical Small Pharma Wholesaler Assessment
Net Assets £79,061 £250k-£2M+ Significantly below range
Total Assets £160,631 £500k-£5M+ Materially sub-scale
Employees 0 3-15 Non-operational profile
Asset Trend (10yr) -69% decline Growth or stable Severe contraction
Share Capital £100 £1,000-£50,000 Minimal capital base

The decade-long erosion of the balance sheet is striking: net assets peaked at £257,517 in 2015 and have declined to £79,061 by 2024, representing a 69% destruction of shareholder value over the period. This contrasts sharply with the broader pharmaceutical wholesale sector, which has experienced steady revenue growth driven by increasing NHS pharmaceutical expenditure and demographic demand pressures.

The company's current ratio (current assets ÷ current liabilities) stands at approximately 1.68x (£160,519 ÷ £95,825), which appears adequate on the surface but must be contextualised against the minimal fixed asset base of just £112 and the absence of any trading workforce. The working capital position of £79,694 net current assets is insufficient to sustain meaningful wholesale operations, which typically require significant inventory holdings and extended credit terms.

Critically, the zero-employee status in 2024 (down from one employee in 2023) suggests the company has essentially ceased active trading operations and is managing down residual balances. This is a pattern commonly observed in pharmaceutical wholesalers that have lost their MHRA wholesale dealer's licence or have been unable to maintain GDP-compliant operations.

The prepayment of £15,000 carried consistently across years may represent a deposit or advance relating to premises or regulatory licensing, though its persistence without change raises questions about recoverability or classification.

3. Sector Trends Impact

Several macro and structural trends in the UK pharmaceutical wholesale market contextualise JANVIT LTD's decline:

Market Consolidation: The sector has undergone significant consolidation, with the three largest distributors now controlling approximately 80% of UK pharmaceutical wholesale volume. Independent and small-scale wholesalers have faced acute margin pressure as manufacturers and buying groups have favoured larger distribution partners offering national coverage and next-day delivery guarantees. JANVIT's contraction from £597,581 in total assets (2015) to £160,631 (2024) mirrors the broader attrition of sub-scale operators unable to compete on service breadth or purchasing terms.

NHS Pricing Pressure: The ongoing expansion of the NHS Drug Tariff's Category M (which sets reimbursement prices for community pharmacies) has compressed wholesale margins. The shift towards direct-to-pharmacy (DTP) distribution models by pharmaceutical manufacturers has further disintermediated traditional wholesalers, particularly smaller operators lacking the volume to negotiate favourable terms.

Regulatory Burden: Implementation of the Falsified Medicines Directive (FMD) in 2019 imposed significant compliance costs on wholesalers, including serialization verification systems and GDP-enhanced warehousing requirements. For a micro-entity with zero employees, maintaining these regulatory standards is economically unviable without substantial investment – a likely contributing factor to the company's operational wind-down.

Brexit Supply Chain Disruption: Post-Brexit customs requirements and parallel import complications have disproportionately affected smaller pharmaceutical wholesalers that historically relied on parallel trade from EU member states. JANVIT's secondary SIC code (46900 – non-specialised wholesale) suggests it may have had exposure to this trade.

Post-Pandemic Normalisation: The 2021 balance sheet showed a brief recovery in total assets to £252,671 (likely reflecting COVID-era pharmaceutical demand surges), but this proved transitory, with assets declining 36% by 2024 as the market normalised and sub-scale operators lost pandemic-era volume.

4. Competitive Positioning

Strengths: - Long corporate history: 25+ years of incorporation suggests established relationships and market knowledge, though this legacy value appears largely depleted - Debt-free structure: The absence of long-term liabilities provides optionality, though this is largely irrelevant given the minimal scale of operations - Low overhead model: Zero employees and care-of-accountants registered address indicate minimal fixed cost commitments, appropriate for an asset-runoff scenario

Weaknesses: - Sub-scale operations: With £160,631 in total assets and zero employees, JANVIT cannot meet the minimum viable scale for competitive pharmaceutical wholesale operations, which typically requires £5M+ in turnover to achieve basic purchasing leverage - No visible trading infrastructure: The negligible fixed asset base (£112) indicates no warehousing, cold-chain, or distribution capability – essential prerequisites for pharmaceutical wholesale - Governance concerns: The simultaneous resignation of two directors (name shown to subscribers and name shown to subscribers) in November 2025, coupled with the historical name changes (from AZTEC ASSOCIATES to WARMAN-FREED to JANVIT), suggests corporate restructuring activity that may indicate a business in transition or wind-down - Minimal capitalisation: £100 in share capital is at the lowest end of the spectrum and provides no cushion for operational shocks or regulatory investment - Declining asset quality: The consistent erosion of net assets over a decade, with no year of meaningful recovery, indicates a business that is consuming rather than generating value

Competitive Assessment: JANVIT LTD occupies a peripheral, declining position within the pharmaceutical wholesale sector. It does not meet the minimum operational thresholds for a viable wholesaler in the current market environment. The company most closely resembles a dormant or near-dormant vehicle managing residual balances rather than an active market participant. Its profile is consistent with businesses that have either lost their wholesale dealer's licence, exited active trading, or are being prepared for dissolution following asset realisation.

The concentration of control between two related PSCs (name shown to subscribers and name shown to subscribers, each holding 25-50% of shares) with the director resignations suggests a family business in the final stages of managed wind-down, rather than an enterprise positioning for competitive renewal.

Names of the people mentioned are shown to subscribers. See subscription

Perspective: Industry Sector Analyst · Model: glm-5.1 · Generated 23 September 2026